JCAD: a new GWAS target to reduce residual cardiovascular risk?

Eur Heart J. 2023 May 21;44(20):1834-1836. doi: 10.1093/eurheartj/ehac708.

Abstract

Divergent spectrum of the mechanisms of residual cardiovascular risk linked to JCAD that could be therapeutically targeted in the future.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cardiovascular Diseases* / genetics
  • Cardiovascular Diseases* / prevention & control
  • Genome-Wide Association Study
  • Heart Disease Risk Factors
  • Humans
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • Risk Factors
  • Thrombosis*

Substances

  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt